In short
Podcast Summary: CNBC's "Fast Money" - Episode: Nvidia’s Rough Week… And Why Users Start & Stop GLP-1 Drugs (1/31/25)
Episode Overview In this episode of CNBC's "Fast Money," hosted by Melissa Lee, the focus is on the recent performance of Nvidia amidst market turbulence, concerns over ongoing tariffs, and a new study revealing insights into the usage of GLP-1 obesity drugs. The discussion features a panel of expert traders: Tim Seymour, Courtney Garcia, Dan Nathan, and Carter Braxton Wirth.
---
Key Topics Discussed
- Nvidia's Market Challenges
- Nvidia shares dropped over 15% in the week leading up to the episode, entering bear market territory.
- Concerns were raised about:
- DeepSeek AI model from China impacting Nvidia's market.
- Broader implications for the tech sector, particularly semiconductors.
- Discussion on whether this represents the start of a "great rotation" away from tech stocks.
- Market Reactions to Tariffs
- President Trump's announcement of new tariffs on Canada, Mexico, and China:
- Tariff rates: 25% on Canada and Mexico, 10% on China.
- Tariff implications for various sectors, specifically tech and pharmaceuticals.
- Traders expressed mixed feelings about the potential impact on the market:
- Concerns about deteriorating economic demand.
- Potential for the stronger U.S. dollar to mitigate inflation impacts.
- Insights into GLP-1 Drugs
- Discussion on a new study investigating why patients start and stop using GLP-1 drugs for weight loss.
- Findings:
- Patients without type 2 diabetes are more likely to discontinue treatment.
- Weight loss correlates with decreased likelihood of stopping usage.
- Income levels significantly influence the ability to sustain treatment.
- Implications for major pharmaceutical companies like Eli Lilly and Novo Nordisk.
- Sector Performances and Investments
- Other sectors (communication services, staples, health care, financials) showed gains while tech struggled.
- Discussion on the potential for a market rotation toward non-tech stocks:
- Traders noted the need for balance across sectors, especially in light of tech's previous dominance.
- Earnings Reports and Future Outlook
- Review of recent earnings from companies like ExxonMobil and Chevron, highlighting refining challenges.
- Discussion on long-term prospects for energy stocks amidst fluctuating markets and tariffs.
- Panelists shared views on whether to capitalize on recent stock drops or wait for market stabilization.
---
Key Takeaways
- The tech sector, particularly Nvidia, is under significant pressure, leading to speculation about a potential shift in investor focus.
- Tariffs announced by the Trump administration are expected to affect various sectors, especially tech, raising concerns about inflation and economic demand.
- The study on GLP-1 drugs reveals critical insights that could impact future pharmaceutical strategies and patient retention.
- The market's current environment suggests opportunities in other sectors, prompting traders to consider diversification away from tech-heavy portfolios.
---
Conclusion The episode dives deep into pressing financial topics, providing actionable insights for investors. The discussion stresses the importance of adapting investment strategies in response to shifting market dynamics, particularly in tech and healthcare sectors.
For more updates and in-depth analysis, visit [Fast Money on CNBC](http://fastmoney.cnbc.com).
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:02Live from the Nasdaq market site in the heart of New York City's Times Square, this is Fast Money. Here's what's on tap tonight. Under pressure, NVIDIA shares sinking over 15 % this week as deep-seeking trade fears roil the semi-sector. Is this finally the start of the great rotation out of tech? We'll debate that. And a new study into the reasons patients stop and restart using weight loss drugs. We'll talk to the lead author to find out what it could mean for the GLP-1 market. Plus, shares of deckers get decked after earnings. The chartmaster lays out his potential breakout stars. And the NASDAQ 100 turns 40.
0:35how the index has changed over the years and what it says about investor appetites. I'm Melissa Lee. Come to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Courtney Garcia, Dan Nathan, and Carter Braxton Wirth. We're going to get to the NVIDIA sell-off in just a moment, but we do want to start with a sweeping announcement from the president that sent stocks sharply lower late in the session. Trump confirming the tariffs on Canada, Mexico, and China will go into effect tomorrow and promising levies are coming for chips, energy, and metals. CNBC's Megan Cassell has got all the latest.
1:04Megan. Melissa, we just finished hearing from the president from the Oval Office, spent about 30 minutes talking to reporters and clarifying his views on all of these points, saying that, yes, those tariffs will be taking effect beginning tomorrow. It's going to be 25 percent on Canada and Mexico, 10 percent on China. He says it's going to be entirely because of the flow of fentanyl. He also said, quote, we are not looking for a concession, suggesting that at this point there is nothing left that any of the three countries could do in order to escape those tariffs taking effect within 24 hours.
1:34He also said the tariff rate could increase substantially, but it also could not, leaving the door open for some changes there. He also said that on Canadian crude oil specifically, he would probably reduce that tariff rate to 10 percent. All other Canadian goods will see a 25 percent tariff, but Canadian crude is likely going to see only a 10 percent tariff. He then spent a lot of time talking about many more sets of tariffs that he is considering that are likely to take effect in the future, specifically on oil and gas. He says around February 18th, they're looking at putting tariffs on oil and gas from all countries.
2:07It sounds like he also mentioned chips and things associated with chips, steel and aluminum higher than he imposed in the first term. He also said copper, but said that one would take a little bit longer, presumably because it requires an investigation. And then he spoke about various forms of medicines and pharmaceuticals that he wants to see tariffs on as well. He also was asked whether he's thinking about putting tariffs on all goods coming in from the European Union? And he said, absolutely. He sees a lot of issues with that trading relationships with the EU. So more to come on that front as well.
2:37And then finally, he was also talking a little bit about any reaction to the tariffs. He says that he's not concerned about market reaction to these tariffs. He says tariffs don't cause inflation. In his words, they cause success. And that while there could be some temporary short-term disruption, people will understand that, Melissa. So a whole lot there to sift through on tariffs. And then just one final headline to bring you, since we just hit 5 p.m., CBS News is reporting that Trump officials are putting a pause on most federal government websites beginning now at 5 p.m. We are seeing some beginning to come down, presumably that's so those agencies can begin to scrub their websites for anything mentioning diversity, equity and inclusion.
3:14So more to watch on that front as well, Melissa. Megan, thank you. That was a lot. Megan Casella from Washington, D.C. By the way, Trump also said we'll be doing something very substantial and terrorist with the European Union. So we are seeing sharp reactions in the currency markets to a lot of these headlines, peso, Canadian dollar, as well as the euro taking a hit on the back. But what's your initial take here? We sort of knew this was going to happen. We didn't know it was going to happen in quite this way. We didn't know it was going to. But here we are. We didn't know Saturday. We heard March 1.
3:45I thought March 1 was the headline this morning for Canada and Mexico. Actually, we started to digest that yesterday. China, we've had this number out there. 10 percent on some level has already been in the market and already kind of a relief. The concept of this being to reverse flow of illegal immigrants and illegal drugs is, you know, one way to get going on it. I mean, there's a lot of different rationale out there from the administration as to why these things are happening. Ultimately, it's really about a competitive balance that they believe anyone who's in deficit, we're in deficit, too, should be tariffs put on them.
4:16It's interesting to think about the currency markets because going into this, you can make an argument that the U.S. dollar was already strong and that there was a lot of pressure actually potentially on multinationals in this country because of the stronger dollar. We started to hear about that in earnings season. When I hear that, at least at this stage of a cycle, it doesn't really bother me as an investor for a lot of these companies. But for the European Union, which had a 25 basis point cut this week, ECB, if anything, was rumored to maybe they could go more, they will go more. I think we're breaking parity here.
4:45And I think and I think it will be just to be clear, I think that will be a mitigating factor on inflation. I think a stronger dollar certainly will have more buying power and be helpful. But we don't really know what the impact of all this. And it's just interesting to see how quickly tariffs have come back into the market, which closed on the lows today. But think about where we were a week ago. Yeah. So, you know, he said that he doesn't expect the markets to be affected and that it's not going to affect inflation. I'll just make this point. We just got this GDP number at two point three percent.
5:11This is after two consecutive 3 % GDP prints, you know, quarterly. And so the economy was kind of limping in to the end of the year. I think expectations were higher than that for Q4. So one of the things we can be fairly certain on, if these sorts of tariffs stay on some of these key industries, it is going to weaken economic demand here. It just will. And so at the end of the day, you know, the president uses the stock market as a report card. But if the economy starts to weaken, the S &P is going to start to anticipate that. I mean, the dollar obviously is such an important thing. The sector, of course, or the area of the market that has the biggest exposure is tech.
5:45I mean, bar none, right? So obviously the big consumer staples, the big energy names. But technology is the highest sort of exposure to a weak or strong dollar. And it's no nonsense when the S &P is doing one thing, but the tech now down on the year. You've got semis struggling. And I think a lot of it has to do with not only the great appreciation that preceded this start to the year, but the dollar. Right. Yeah, and I think a lot of this, too, people were wondering, are the tariffs just going to be negotiation tactics or are these actually going to come on? And clearly we're seeing these are coming on.
6:16And this is why the bond markets have been pricing in inflation. I mean, this, whether it's tariffs, whether it's tax cuts, I mean, a lot of these are inflationary policies. And that is why markets are concerned about where inflation is going. So they're optimistic about deregulation. They are worried about inflation. Markets are kind of up and down as they're trying to figure out where that's going to go. But I would expect that's going to continue to affect the markets as this news continues to come out. I mean, we've been thinking about oil and gas and commodities and so on in terms of the impact of tariffs.
6:43But when you think about pharmaceuticals, you know, you think about the inputs into drugs that are manufactured here in the United States, but the inputs come from abroad, that's where you start thinking maybe we have not yet really fully digested the impact of tariffs and the ripple effects that it can have across several different industries. Well, and that's it. And we hadn't really heard a whole lot about the impact for health care, but certainly for pharma specifically. And so that's part of where the market's uncertainty around really what's going to what's coming next. What kind of teeth will there be attached to this?
7:13You know, the other side of what we were hearing before we heard about starting Saturday with Canada and Mexico is that, OK, there'll be some offsets. There's going to be a lot of trading going on between the lines and that, you know, maybe the headlines will be busier than than actually the reality of this. So I get back to markets, which today also had to digest a PCE number, which most people know is a big a big number for the Fed to follow, which came in significantly higher. against all relative than expected. So to the extent that inflation is something that we're still fighting, we had a Fed this week that pretty much kind of said as much.
7:44They argued that the change in the language was really just to clean up the statement a little bit. But the reality is inflation is still an issue here. And markets, especially the part of the market, Carter's referring to the tech world. I mean, let's be clear. Mega cap tech should be the most insulated from inflation here. And that is what seems to be struggling. Yeah, let's talk about that here. because NVIDIA really closed out a rough week here. The stock unable to rebound from Monday's deep-seek scare. It is down nearly 16 percent since then. That is its worst week since September 2022. NVIDIA now off more than 21 percent off-record highs.
8:19Hit the start of the month, putting it firmly in bear market territory. But while tech and semis put pressure on the broader markets, there were some winners here on the week. Communication services, staples, health care, financials, posting solid gains. We saw this on Monday, too. We saw good breath in the market outside of technology. So is this the start of a rotation that may stick here, Carter? Well, the one thing about communications is they change. We know as AT &T and Verizon, what they got in there is Google, Netflix. Those are tech. So certain tech, let's just call it tech, is holding up well, whereas semis and AI and some of this stuff is struggling.
8:52So a very mixed bag on that score. But it is important that the things that really led us are starting to churn and struggle. Yeah. What do you make of the sort of rotation that we saw this week? Yeah, and this is really what we've been looking to do the last several months. I don't necessarily think that there is some downturn that's coming in tech or AI. I think some of this that's happening with D.C. is probably a little bit overblown here. But I do think you want to be looking at those other areas of the market. You want to be looking at things like banks and things like cyclicals. I think a lot of those are going to continue to do well here.
9:22And I think when you look at AI, especially with the news this week, if it really is as cheap and as quick to create as they're saying, And I know there's a lot of questions about that. The way to play that is with the other 493 stocks in the S &P of F100. If it's going to become much more accessible to these other companies, it's going to really increase productivity. It's going to make them much more efficient. Yes, it might be a longer term play, but I think it's going to be a good thing for the markets in the long run. But the overall market is not just those seven companies. And by the way, it's not just DeepSeek on NVIDIA.
9:49It's tariffs, right? So if they have faced further curbs in terms of the kinds of chips they can sell to China and their revenues will be limited in that respect. on top of the DeepSeek scare. I mean, there are a couple of reasons why you might be scared. Yeah, and before DeepSeek, we were already starting to wonder if there was an overbuild as far as infrastructure is concerned. A lot of these companies that actually need the chips and are building out the data centers, I mean, they had been ordering fairly aggressively. At some point, you're going to see a drop-off in that order. We've already seen deceleration of growth in NVIDIA.
10:16I mean, a lot of folks have been waiting for this in NVIDIA. And again, down what, 20 %? You just said from the highs. You know, go back to last summer into early August. NVIDIA was down 35%. So this is kind of the run-of-the-mill sort of move for NVIDIA, except this time it really does seem about something fundamental. The last time it was technical. It was momentum-driven. It was very crowded. I think since then we had some of the guys like Marvel and Broadcom join the party because some of NVIDIA's largest customers had been contracting with them to make specialized chips for products and services.
10:48That was always going to happen, right? What we didn't see is AMD and Intel join the party, right? So the semi-trade was very, very narrow. The last thing I'll just say is that, you know, Microsoft and those results, I mean, we haven't even mentioned that yet. Down 6%. It's been a massive underperformer. Microsoft was one of the early beneficiaries in the stock market early 23 from their partnership with OpenAI. So think about everything we learned here. Maybe these hyperscalers don't need as many chips to train the models and make new models. All right. So that happened this week. Then we have a situation where OpenAI and Microsoft, their relationship has been fraying a little bit.
11:23OpenAI is a big customer of Microsoft's Azure cloud, right? And so at the end of the day, you know, there's definitely some push and pull there. Last thing, OpenAI is in the market to raise tens of billions of dollars right now that SoftBank is supposedly going to kind of leave. So a lot of things, a little bit for everybody. To me, it really feels like this trade is cooling a little bit. And in terms of rotation, which is obviously always a part of markets trying to figure out where you can win or deliver alpha, the biggest single rotation in your data, of course, is Europe, right? And that's value, right?
11:52So you're talking about the stocks 600 in Europe, our equivalent S &P, is a 15 PE. It's up 7.5%. The DAX, the big player, Germany's up 8.5%. And so there's very little tech there. There's very little AI. There's very little anything except big, heavy industrials, banks, energy stocks that have lagged. And money has gone there. That's the biggest single rotation going on. I agree with that. I run an international ETF. I mean, I see the European banks with, I think, balance sheets that are as good as the American ones. People think that Europe's a mess. It is in terms of the public side of it. But again, the private banks, even though you can argue Deutsche Bank is a quasi sovereign.
12:26The end of the day, ECB is probably still the place you'd be most worried. European banks are paying high dims. They're cheaper. SAP, Siemens. I mean, think about the industrial spot across Europe, which has underperformed over the last couple of years. Remember, the underperformance of the Mag 7 or at least the top five tech companies in the world is partially a partially at least what was a big impact to the headwinds on investing around the world. Again, there was a crowding out effect. So I like that call. I continue to think that you could look all the way back to March of last year and say semi's peak there.
12:57I mean, outside of NVIDIA, you could look at AMD. I mean, AMD has hurt a lot of investors over the last 18 months. It happens to be the A in band, by the way. So it may be a different year. But anyway, I think it's a fascinating time. You wanted broadening. You're getting it. All right. Meantime, well, stocks ended the month on a down note. Our next guest says the markets and Fed are overly sanguine on growth and overly pessimistic on inflation. Jack Genesiewicz of Natixis Investment Managers joins us now on the Fast Line. JJ, great to have you with us. A week ago, we didn't have all this cascade of tariffs coming down the pike on Saturday.
13:31We didn't have the deep-seek scare. Does your view of the market change? You know, I think you still have to look at the underlying dynamics here, and the fundamentals of the U.S. economy are still very strong. You know, and we're looking at nominal growth coming in probably closer to 4 % for the full year, slowing from 5%, and that's still above trend levels. And so when you think about that backdrop, that's still pretty good for, I think, corporate earnings here, and that's still what it all comes down to. So look past a little bit of this geopolitical noise, and really the underlying story here is the foundational economic backdrop for the U.S.
14:04economy is still pretty robust. I completely get that you can say it's noise. I mean, the ExxonMobil CEO on the conference call actually said, you know, tariffs are just speculation that it's been driven higher by the media. So there is that point of view. But corporate earnings, in some respects, I mean, it's backward looking. Granted, the guidance is forward looking. But right now, the snapshots that we're getting is the reflection of an economy that is a capsule in time that is no longer the economy we now have with tariffs in place. How do you interpret the impact of tariffs, even if it is in the next three to six months?
14:37Because the next three to six months impacts the guide that companies are giving now, as well as a guide for the rest of the year. And that's going to be a wild card, I think, going forward, right? Because, you know, we've heard starts and fits, right? On day one, we were supposed to get tariffs. We didn't. Then we were going to see Columbia being tariff. Well, they backed down on that one. You know, then it was, well, March 1st. Now it's February 1st. So, you know, a lot of this is still a lot of headline news coming out. So it's really difficult, I think, to really adjust portfolios here because the bottom line, tariffs are still probably going to be a negotiation tool.
15:08You're going to start high, ratchet it back down until you get something. But that number, if we end up having to implement tariffs, probably going to be something much lower and maybe less impactful. So I hate to say it, but you almost have to be reactionary with some of this stuff rather than proactive. And Jack, this is Courtney here. Thanks for coming. I'm curious about your outlook on inflation. Right. So you actually mentioned here that people are overly pessimistic with inflation. And I'm curious here if inflation kind of stays where it's at. We have this higher for longer rates. They're not going up and not coming down from here.
15:36Do you see that as problematic or can the economy continue to do well with where rates and inflation currently are? You know, I think we're in an OK spot. You know, I certainly would like to see rates continuing to come down something closer to the low fours or the higher threes with the tenure. But when I take a step back and look at the inflation backdrop, I think the big picture level says it all. Right. And we're seeing the labor market slow. As a result, you should expect to see wage growth continuing to come down. And then, you know, from that perspective, where do you get the demand pull from?
16:08And then you start looking at what's going on with regard to housing. You know, you look at all the real-time indicators, and that continues to come down. So between those two things, I certainly have a hard time seeing inflation reaccelerating. Maybe it comes down slower than expected, but I think it still heads lower. And that, I think, you know, basically plays to the idea that maybe we should be expecting more cuts than hikes in here over the rest of 2025. Jack, great to speak with you. Thanks for your time. Appreciate it. Thank you. Jack Janosiewicz, do you agree with JJ? Well, you know, cuts as we get back into the second half of the year may be a reality.
16:42I mean, the Fed's going to be watching the labor market, you know, laser focused on the dynamics that I think looked kind of weak last fall, which put the 50 BIP moved out of the gates. I think the markets right now are certainly trying to digest where we've had a tremendous headwind from things that we just don't know about. I think this week shook markets to their core. You had a challenge, at least to the whole ethos around the chip world and the infrastructure spend around it. You also had dynamics around tariffs that we didn't think. I also just think the strategic war with China as it relates to chips, how important companies like Taiwan Semi are in the global sphere and how worried we should be in the U.S.
17:19if some of these things get a lot worse. That's what this week was about. We came into this week feeling almost breathless and without any concern. And, you know, welcome to reality. Yeah. You know, listen again on the inflation stuff. If tariffs come in and they stay here and they cause the economy to weaken, inflation is going to come down. I mean, like that's just going to happen here. And again, you know, we were worried about stagflation. But look at the numbers that we put up last year with inflation on a cumulative level still pretty high. So at the end of the day, you know, we went from talking about rate hikes maybe in the back half of this year to possibly going back to if I'm looking at the CME FedWatch tool, I'm looking at June.
17:55And it's still pricing about a 50 percent probability of four and a quarter on the upper band. So that would be another 25 basis points. You know, like it's a coin flip. So at the end of the day, I just think that inflation probably topped out is my guess. And, you know, now it's up to the economy just to try to hang in there a little bit. Coming up, more on tariff turmoil in the energy sector. Oil closing out a losing week and two energy giants commenting on the moves in their latest earnings reports. More on that next. Plus, hitting the deck, the parent company of UGG and Hoka plunging despite raising full year guidance.
18:27The details on that disconnect right after this. This is Fast Money with Melissa Lee, right here on CNBC.
18:44We've got breaking news on charges against a former Fed official. Steve Leisman's got the details. Steve. Thank you, Melissa. Yes, the Justice Department just the last hour charged a former senior Federal Reserve official with conspiracy to commit economic espionage. The justice says a 63-year-old John Harold Rogers is alleged to have passed, quote, sensitive trade secret information from the Federal Reserve to co-conspirators in China. Rogers was sent specifically to solicit briefing books for governors, proprietary data sets, and sensitive information about FOMC deliberations. Apparently, he printed this info out or sent it to his personal email in violation of Federal Reserve rules in preparation for trips to China.
19:27Rogers allegedly made false statements to the Federal Reserve's inspector general about accessing and passage of this information, as well as an association with co-conspirators. He worked as a Fed senior advisor in the Division of International Finance from 2010 to 2021. These alleged actions ran from 2013 to 2025 in the indictment. says that's even after he left the Fed. The Justice Department says the info was passed, that Roger's past was, quote, economically valuable. They went on to say that the data provided could allow China to manipulate U.S. markets. He provided info, quote, under the guise of teaching classes.
20:09The indictment cites two unnamed co-conspirators who worked, who the indictment says worked for the Chinese intelligence apparatus and presented themselves as graduate students. He was paid$450 ,000 in 2023 as a part-time professor at a Chinese university. The Fed declined to make any public comments about this, and the Federal Reserve Inspector General, who was involved in this but is quoted in this, could not immediately be reached for comment, Melissa. Wow. Steve, thank you. Steve Leisman. Pleasure. A pair of oil giants dropping after their earnings reports this morning. Chevron missing Q4 profit estimates with the company's refining business, posting its first loss in four years.
20:46Meantime, Exxon beating on APS but coming up short on revenue. These moves coming as President Trump plans to put tariffs on oil from Mexico and Canada starting tomorrow. What did you make of interesting moves here, especially Exxon Mobil? Well, I thought the moves in the stocks were very overly sensitive to the refining margins and the refining misses because Exxon is the same thing. The upstream beat, first of all, the free cash flow beat in both places. And I still think that that's what you want to be most focused on along with CapEx if you're an investor in the integrated. I like the European ones even more.
Read the full transcript
21:16But I like Chevron, if you remember, of course, it was the C in Blysep, I think, at this point. Who knows? But I like it today. I liked it last year. I like Exxon. Exxon is recently as March, excuse me, as October, was looked like it was breaking out to fresh all-time highs. And it's pulled back. And in fact, you can make an argument, it's done almost nothing over the last couple of years after energy really outperformed. So I think the energy names, I guess it's funny. I don't think that they're really the ones caught in the line of fire on the tariff dynamics, especially companies like Exxon, especially, which is a global company and has a lot of their assets around the world.
21:52We'll see. I don't think that was the reaction today. Exxon CEO said, you know, we think we'll do fine under this tariff scenario because we can produce oil more efficiently than our peers. And that's the benefit of being a large integrated. Yeah. And I think, too, when it came to Chevron, what you're seeing there is there's a lot of still pressure with their Hess deal. And I think there's a lot of questions there and they're likely not going to get answers until the end of this year. So I think some of that's probably why you're seeing a little more pressure on Chevron than you are Exxon because both of them had like refinery issues that I think were the biggest things that we saw there.
22:19But I think what's interesting longer term is Chevron is getting in this space of producing power plants. And that was something this week that we saw everyone saying, oh, we might not need as much energy if AI is much cheaper to produce. But a lot of that demand is going to come from things like manufacturing on shoring, electric vehicles, electrification of the economy. So I think a lot of that longer term is actually still a really big opportunity. I mean, it's such a curious space, Right. Because it's not a big part of the market. Right. Energy at three plus percent. The two or three big stocks are half the way it kind of goes.
22:47But it's also you think of it as dull, but it's it's really high beta. Right. So it it really underperforms in 18, 19 and energy really outperforms in 2021. And now it's been sort of the opposite since 22. Ultimately, the yields are safe. I think we'd agree on that. And I think they belong in every portfolio to some extent. All right. So 25 percent tariffs on our biggest trading partners, Canada and Mexico, these large integrated names. They get a lot of oil right from those two countries. They refine them here. Their margins are going to be down. That was one of the reasons that these stocks sold off.
23:19And the Chevron CEO on the call this morning referred to the Gulf of Mexico as the Gulf of America. These guys are so far up. You know what? Like they just got to get their head straight a little bit, do their business. You know what I mean? And again, maybe affect the tariff conversation more so than just kind of some of the narratives in and around the new administration. There's a lot more Fast Money to come. Here's what's coming up next. Hitting the deck. Shares of UGG and Hoka Parent deckers coming untied despite a beat and raise. Why investors are running away from this running shoemaker.
23:51Next. Plus, a new wrinkle in the obesity trade. The numbers behind why so many patients ditch GLP-1 drugs and the data that could tip the scales. You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.
24:18Welcome back to Fast Money, a buzzkill on Deckers, the name behind Ugg boots and Hoka sneakers. Shares plunging 20 % after the company gave a disappointing sales outlook for the current quarter, raising guidance by less than it beat. The stock closed at a record high yesterday, but today saw its worst drop since 2012. Concerned that Hoka's, the growth is slowing there. It had been so hot, it seemed to be taking shares from Nike and everybody in the world. Everybody's wearing Hoka's and A's. And Uggs. And look, at some point, you are a victim of your own success. And I just think that that's really, look, if anything, what they've guided would mean comps would be negative for the first time since 2019.
24:56I mean, it's a really, really tough comp. It was an incredibly strong holiday season, to be clear. And I think there's a lot of analysts on the street right now that say this is weakness to buy, that the guide was overly conservative. So that's really the dilemma here. Remember, you know, Lulu, when it went through that period where, again, it was too good to be true. And, in fact, the multiple wasn't that awful, but it wasn't necessarily a sure thing on growing at the same rate. And I think that's the issue here. Yeah, UBS said it's a buying opportunity. Do the charts say that, Carter? Well, so it's always that question.
25:27And there's two types of weakness in principle. Weakness to take advantage of and weakness to stay away from, right? It always sounds so simple. But it's not that simple. Clearly, there are two choices here. No, right? I mean, think about it. And so there are two types of discounts. And I would just put it in this context. If beautiful blazers or casual sweaters are all$1 ,000. Yes, and that is a beautiful blazer, by the way. Not mine. And then they put it on for$700 instead of$1 ,000. Nothing's changed about the blazer or sweater. That's a discount. That's weakness you want to take advantage of.
25:56But discount sushi? That's called rotten fish, right? So you don't. Wow. So here's what we're dealing with. Is there something wrong with this? Is this a discount to take advantage of, or is it weakness they weigh from? In principle, you don't want to buy after a first-day drop-in gap. When volume is eightfold, tenfold, not good technique. All right, so is this a blazer on sale, or is this rotten fish, Courtney? I really like the analogies, Carter. I'm really enjoying this. Which do you think? You know, I think when it comes to a company like this, like they have always been pitted against Nike, to your point, because they're taking a lot of share.
26:30But I do think you get this fragmented space, right? Like athleisure was the space during COVID. And now there's people, you know, we're not wearing athleisure as much, but also there's just so many more options. And I wonder just how much of that you're seeing reflected in the demand story. So, yeah, I don't know if I would jump in with two feet on this one, but I don't know if it's rotten sushi either. I think it's probably somewhere in between. It doesn't have to be, right? But the question is, obviously, as a matter of technique, all kind of analogies and jokes aside. it's usually better to let the dust settle.
26:56Right. Yeah, really quickly. I just think that when you see a move like that from an all-time high, you take out two months of performance in one gap, it just speaks to a level of complacency. And so, again, I think that a bunch of names that were growth stocks are starting to see deceleration. I think that's something we see into mid-year. Coming up, ditching the drugs. Why so many GLP-1 users quit and what the numbers could mean for names like Eli Lilly and Novo Nordisk right after this.
27:24Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
27:40Welcome back to Fast Money. As people scramble to get their hands on GLP-1 drugs, the first of its kind study is examining reasons why patients discontinue or reinitiate obesity drug treatment. Research is finding that patients without type 2 diabetes are more likely to discontinue treatment, while other factors like income and drug side effects are also playing major roles. Lead study author Tricia Rodriguez joins us now. She's a senior applied research scientist at Truveda. Tricia, great to have you with us. This is a fascinating study, particularly as companies are looking at ways to, I guess, keep people taking these drugs.
28:14What was interesting to me was, you know, I think that there was an assumption in the marketplace somewhat that if people saw a great weight loss, they were very successful on these drugs, that they might stop and try and just keep it off on their own. But that's not what you found. Those people are more likely to stay. Thanks so much for having me. That's exactly right, Melissa. We found that weight loss was associated with a lower likelihood of discontinuation. So as patients lost more weight, they were less likely to stop the drug. And in terms of, I mean, everything is a choice, right, in life.
28:46So also income has something to do with it and the cost. What did you find? Yes. So we found significant relationships with income, particularly for patients with type 2 diabetes. And this was really interesting because what we saw is that as income bracket increased, the likelihood of stopping progressively decreased. And then the flip side of the coin, of course, is cost. And on the cost side, we see that this much higher rate of discontinuation for patients that don't have type 2 diabetes, we know those patients face a much higher burden of cost because insurance is a lot more challenging for those patients.
29:26And so both from the income and the cost perspective, those seem to be playing a really important role in discontinuation. In terms of, I mean, just going back to the grade of the weight loss, what were, I mean, it actually, you sort of sliced into very fine tranches in terms of how much weight loss is associated with a likelihood of discontinuation, which I thought was really fascinating. Yeah, so we looked at the sort of time varying weight loss. And so each 1 % weight loss was associated with about a 3 % reduction in actually stopping the medication. And what is sort of the takeaway of this study overall in terms of, you know, if you're Eli Lilly or Novo Nordisk and you're taking a look at this data and you're thinking, how do I get patients to stay with the drug?
30:12What are some of the high level findings that you have in terms of the patients who are more likely to stay on the drugs are patients who are what? Right. It's a great question. And so the patients who are more likely to stay on the drugs are, of course, patients that don't experience moderate to severe adverse events. They're also likelier to be experiencing a benefit. But I think the really critical piece here is that there is a gap in access. And so the highest income patients are able to stay on this drug, while lower income patients are less likely to stay on this drug. And so I think that's a really key takeaway of this study is sort of how can we enable greater access for a greater range of patients.
30:56All right. Tricia, great to speak with you. Thank you for sharing the results of this study. Really interesting. Thank you so much. Tricia Rodriguez of TruVeta. And, you know, that issue of access and you wonder how much of it will be opened up as more indications are approved by the FDA for taking these drugs. And then also, as there are different form factors, pills theoretically should be cheaper to manufacture, should be cheaper to buy. And will that open up the audience? Well, right. The uncertainty about just what the competition looks like. And then with the supply demand kind of picture kind of getting a bit more in line.
31:28I mean, the stocks tell you everything you need to know, Lilly and Novo. And, you know, they're not too different than we talked about this last year, the mega trend of generative AI and GLP ones. and look at the way Novo and Lilly have traded, specifically Novo, over the last, I don't know, six to nine months when it topped out. And those looked a lot like some of these generative AI stocks or specifically like NVIDIA. So I look at a Novo Nordisk. If you tell me that you're not going to have any major competitors in the next year or so, trading at about 22 times this year's expected earnings growth at 22 percent, I know they've already guided down.
31:59Maybe they've de-risked in the near term. But maybe that one looks more interesting. But I think they're both really tough right here. Yeah, I mean, just to Dan's point, think about how long it's been since they've made the simple thing of a 52-week high, right? So Novo peaked last week of June, Lilly in the second week of July. So you have the sort of one-two setup of great proceeding outperformance and then now half a year and more of honor performance. That's usually, it looks like this. Right. Yeah, not great. And then there's also the issue that we saw with Eli Lilly's past earnings releases when they were talking about inventory and how lumpy that is and how analysts are sort of trying to figure out how that is, that it can be so lumped.
32:39But you can't figure out what the inventory is when you have a population of patients who are taking these drugs. There was an analysis by Evercore ISI's Umar Rafat, and he was saying that he believes that seasonality also plays a factor, that they're just learning so much about how these drugs are taken and how long patients stay with it. It sort of gives you an idea that maybe things are not as clear as it's a huge market. It's a huge demand for the drugs. and they're expensive and it's a buy, you know? So I get the lumpiness and I get the fact that the euphoria around GLP is something that, you know, a lot of people, we had the ability at least to make comparisons to semiconductors.
33:16But the reality is that Lilly's compound annual growth rate, at least the analyst community, says it's going to be north of 30 % for the next five years. So is that priced in, especially when you look at the margin profile of the company, which seems to be getting better. So some of the dynamics around the oral and some of the releases on the different phases here, I mean, I think there's going to be catalysts even within GLP, but people forget about where Lilly is in other product classes. So I think this is weakness you're buying. I can't argue with what Carter's saying. I mean, and Novo, I mean, that's been a stock that's hurt people who jumped into that thing late in the game.
33:49Yeah. A buy on Lilly for you or no? Yeah, I think this is something you want to take advantage of, mainly because of the supply and demand constraints, right? I mean, this is an industry that has not been able to get the supply out there to the point that you have these compounded drugs in order to compete. And those are starting to get taken off. Now the supply is there. I mean, the demand is not the question here. I think the question is, are investors going to wrap their head around that? And clearly, you're seeing some of that optimism was priced in. It's getting taken off. But I think over the long run, I think this is something you absolutely want to have a piece of.
34:15Coming up, the NASDAQ 100 is celebrating its 40th birthday. The index has risen by more than 17 ,000 percent since its inception. We'll dig in on the biggest changes in that time and where the trends are going next. But first, points for a pop. The chart master lays out a handful of names he thinks are gearing up for a breakout. But that is next. More Fast Money right after this.
34:44Welcome back to Fast Money. From an infotech stock to a cybersecurity company that relies on artificial intelligence, the chartmaster sees patterns that suggest these stocks may be on the cusp of a breakout. Carter, what are you looking at? Sure. So I thought we would, as an exercise, look at some laggards, right? names that have not made 52-week highs, have not broken out, that have been range-bound. And the thinking is that these are catch-up trades. So rather than chasing some of the steepest extended names, let's run through them. Four charts. The first is Accenture. Of course, they're in IT consulting.
35:14And as annotated here, it is toying with the prospect of moving above the former high. And that's my bet, hence the green arrow. That part's objective, of course. Someone else might draw a red arrow. But anyway, on to the next. And so what you see here is Union Pacific. It's obviously one of the biggest rails. And it, too, has the same circumstance. It has not broken out. And the betting is that it will. Lagging. If the market's making you high and you're sideways for six, eight months, you're not a performer. That's an opportunity or a problem. I think it's an opportunity. The third of the four, again, these are all very large cap,$100 billion plus, is Medtronics.
35:53It's devices. It's health care. And it, too, has not made a 52-week high as the market recently did. Good relative strength this week. Play for the breakout. And then finally, CrowdStrike, also a smaller name, but still$98 billion. And the presumption is, because the pattern is the same, that it, too, is going to break out. So we play the cards as dealt. Do all stocks that are setting up to break out break out? No. But that is the bet. Which do you like, Dan, if any? CrowdStrike is interesting. Remember last summer when this thing got cut in half and one fell swoop? They had that obviously that data issue to me.
36:26I just think, listen, the S &P, it looks fine here. It's back up towards those high. We had that little shake out here. Earning season seems like, you know, it's been OK for the most part. It got off to a great start with banks and the like here. I just think at some point the S &P is likely to take a little bit of a breather here, maybe down five to seven percent or so. So I don't love, you know, a lot of these stocks have come a long way despite the fact that they've been laggard. So I'm just not buying breakouts right here. U.N.P. I mean, we just got numbers out of them. We are hearing about margin improvement, operational efficiency.
36:57You know, there's all kinds of questions about what tariffs might mean if you're a rail. But I think this is one where the valuation and the way they're running the business gives you a reason to say, I can hang in there until this one does break out of that range. Carter says we might be on the verge of. How about you, Court? Rather than picking one, I'm actually going to take Carter's advice. I think what you want to say is probably not all of these are going to break out. But I think this is why you do want to take advantage of the stocks that are out of favor right now. Especially, you know, we've been saying this a lot to clients, but you are likely overexposed to tech.
37:25You want to start to look to take some profits. Take advantage of some of these dips. So don't try to pick one of them. Get diversified. I think, you know, a lot of these are really great names that Carter picks out here. Coming up, Foreigner and Wham. We're talking the Billboard charts. And Beverly Hills Cop, that was blowing up the box office. We're taking it back to 1985 and the debut of the NASDAQ 100. Next, more Fast Money in 2.
37:57Welcome back to Fast Money. Today marks the 40th anniversary of the Nasdaq 100. The index attracts some of the largest non-financial names in the Nasdaq composite. At its inception, its market cap totaled$58 billion. Today, it is worth over$27 trillion. Only six of the original components remain in the index. Apple, Micron, Intel, KLA Corp, Pacar, and Costco. Today, Apple alone is worth about 60 Nasdaq 100s from 1985. We're joined now by Brian Hartigan, Invesco's global head of ETFs and index investment. Invesco manages the QQQ, the fund that tracks the Nasdaq 100. Brian, great to have you with us.
38:37Great. Thanks for having me. And we were just talking about how it's changed so much in the 40-year period and the most remarkable change, not just the size, is a concentration, right, these days. That's right. Yeah, it's really evolved since 40 years ago the index launched. 25 years ago QQQ launched. Really, as I say, one of the leaders of the ETF industry. But you've seen that concentration evolve over time. But what's been true is the index has always captured the secular themes, be it technology, innovation. We talk about the beginning of the Internet days into PC computing, into tablets and smartphones, onto social media and into AI and the like.
39:16So the index has always been able to capture the leaders of that. But this year, you're certainly seeing much more concentration in the top holdings. And that's been a big story around the markets this year. Hey, Brian. Yeah. Congratulations, because ubiquity sometimes is a negative. You've achieved ubiquity. I mean, the associative of the cues to the markets is, as we were saying, like Kleenex to facial tissue. So good for you. And I guess the RSP is outperformed this year. And so after years of, you know, I was probably saying one year ago, I don't think six stocks are going to be 30 percent of the S &P or 36 percent of the NASDAQ.
39:51So just give us your thoughts on the flows there. And I'm curious now just to layer in the institutional versus retail, because institutions, it's no longer an embarrassing thing as a hedge fund guy to say I'm owning ETFs. That's right. You know, and especially these ETFs, which give you a lot of balance. Right. Well, we talk about Q's. Q's is one of the most liquid vehicles in the world. RSP has actually taken on the same institutional liquidity. You know, it's fractions of the S &P and it's multiples of what it used to be in terms of the liquidity. So it does bring in institutional investors to do exactly what it does and diversify from that concentration risk.
40:25So equal weight the 500, you're taking away the MAG-7 and some of that concentration, and you're able to really, you know, surgically insert kind of that allocation, whether it be short-term, long-term, or for your overall portfolio diversification. So we're seeing the institutional adoption and, again, that much more close, hands-on surgical precision that investors are looking for. Brian, give the viewer a sense. Like two years ago, NVIDIA was a$300 billion market cap company. Now it's a$3 trillion market cap company. How do you guys kind of rebalance these sorts of ETFs so you don't get too lopsided towards a few different names?
41:03Sure. Yeah, the Nvidia story is an amazing growth story, and the index captures that, right? Whether it's we have index evolutions from the mid-cap, the next 100, into the ultimate NASDAQ 100, and those rules really create some of the ceilings, right, for diversification rules, minimizing some of the 5 % allocations that you have. So the indexing really takes the rebalancing, the management, kind of keeps buying some of those winners and gets rid of the losers very naturally. through the index process. Do you guys have like cake in the office? Like what do you do for 40? 40, you know, I'd love to celebrate a 40 again.
41:42So this was great. I really enjoyed it. We had cupcakes and we were out on the screen. It was great. Thank you, Brian. Thanks for stopping by. Brian Harding at Invesco. Up next, final trades.
42:00Thank you. I would have done it again. Final trade time. We're having a fascinating stat Carter pulled up. Walmart and Costco beat the NASDAQ over the past 40 years. Incredible. Amazing. OK, final trade time. Tim. Carter is full of those, by the way. And fortunately, we get them all the time on this show. GDX is probably another one. I bet he's done this with gold and the S &P. And it's certainly been a period where gold's had a great run, making fresh new all-time highs. GDX, to me, has been underperforming that. Go buy that. Courtney. You know, we started the show talking about this broadening happening.
42:32and in light of Invesco being here, I do think looking at the RSP, which is the equal weight S &P 500, is absolutely worth taking a look at here. And Nathan? I agree with that, especially when you see some of these big names kind of reverse a little bit. I thought Apple's price action today was really bad. I expect maybe the meta, even though it had a good quarter, to come back into a little bit. Gardner, Braxton, worth of worth, Charlie? Well, got to go with one of those singled out earlier today. So Accenture, obviously, some would say a low beta, boring kind of name, but I think you play it for a breakup.
43:00All right. Thank you for watching Fast Money. Have a terrific weekend. Don't go anywhere. Mad Money with Jim Cramer starts right now.
43:31a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money disclaimer, please visit cnbc.com forward slash Fast Money disclaimer.
From the publisher
Nvidia wrapping up a rough week, as the chip giant enters bear market territory. The concerns surrounding China’s DeepSeek AI model, and if the chip crunch has our traders rethinking tech’s leadership. Plus.. weight loss drugs taking the market by storm, and a new study is diving deeper into why consumers are starting and stopping usage. The factors contributing to their decision, and what it means for the entire obesity drug space.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
